Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

被引：1
|
作者：
Blauvelt, A. [1 ]
Langley, R. [2 ]
Leonardi, C. [3 ]
Gordon, K. [4 ]
Luger, T. [5 ]
Ohtsuki, M. [6 ]
Nickoloff, B. [7 ]
Kerr, L. [7 ]
Mallbris, L. [7 ]
Reich, K. [8 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Northwestern Univ, Feinberg Sch Med, St Louis, MO USA
[5] Univ Munster, Munster, Germany
[6] Jichi Med Univ, Shimotsuke, Japan
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
10.1016/j.jid.2016.06.408
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
388
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [41] Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
    Schwartzman, Sergio
    Sandoval, David
    Kronbergs, Andris
    Lisse, Jeffrey
    Patel, Himanshu
    Xu, Wen
    Liu-Leage, Soyi
    Magrey, Marina
    Marzo-Ortega, Helena
    Poddubnyy, Denis
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] SECUKINUMAB, A FULLY HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, EXHIBITS LOW IMMUNOGENICITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DURING A 52-WEEK TREATMENT PERIOD
    Deodhar, A.
    Gladman, D.
    Mclnnes, I.
    Ren, M.
    Spindeldreher, S.
    Pricop, L.
    Porter, B.
    Safi, J.
    Shete, A.
    Bruin, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 999 - 1000
  • [43] SECUKINUMAB, A FULLY HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, EXHIBITS LOW IMMUNOGENICITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DURING A 52WEEK TREATMENT PERIOD
    McInnes, Iain B.
    Deodhar, Atul
    Gladman, Dafna D.
    Ren, Mengyuan
    Spindeldreher, Sebastian
    Pricop, Luminita
    Porter, Brian
    Safi, Jorge
    Shete, Abhijit
    Bruin, Gerard
    RHEUMATOLOGY, 2019, 58
  • [44] IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment
    Laura Mercurio
    Martina Morelli
    Claudia Scarponi
    Elan Z. Eisenmesser
    Nunzianna Doti
    Gianluca Pagnanelli
    Emanuela Gubinelli
    Cinzia Mazzanti
    Andrea Cavani
    Menotti Ruvo
    Charles A. Dinarello
    Cristina Albanesi
    Stefania Madonna
    Cell Death & Disease, 9
  • [45] METHOTREXATE HEPATOTOXICITY DURING LONG-TERM TREATMENT WITH WEEKLY DOSES IN PATIENTS WITH PSORIASIS
    GROSS, JB
    BEERS, TR
    MCGILL, DB
    HEPATOLOGY, 1989, 10 (04) : 745 - 745
  • [46] Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Ridenour, Terri L.
    Somani, Najwa
    Zhu, Baojin
    Atiya, Bilal
    Lew, Carolyn R.
    Kern, Scott A.
    Zimmerman, Nicole M.
    Murage, Mwangi J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB114 - AB114
  • [47] Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
    Augustin, Mathias
    Gallo, Gaia
    See, Kyoungah
    McKean-Matthews, Missy
    Burge, Russel
    Gooderham, Melinda
    Reich, Kristian
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (02) : 14 - 18
  • [48] Secukinumab exhibits low immunogenicity during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis
    Sinclair, R.
    Reich, K.
    Blauvelt, A.
    Warren, R.
    Szepietowski, J.
    Sigurgeirsson, B.
    Langley, R.
    Tyring, S.
    Messina, I.
    Fox, T.
    Papavassilis, C.
    Bruin, G.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 74
  • [49] First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis
    Kaul, M.
    Jarvis, P.
    Rozenberg, I
    Kolbinger, F.
    Di Padova, F.
    Calonder, C.
    Espie, P.
    Rondeau, J. M.
    Cebe, R.
    Huber, T.
    Mussmann, R.
    Aassi, M.
    Sligh, T. S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1143 - 1151
  • [50] BRODALUMAB Anti-IL-17 Receptor Human Monoclonal Antibody Treatment of Psoriasis Treatment of Asthma
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2012, 37 (12) : 837 - 840
12345